Cadiergues Marie C, Navarro Christelle, Castilla-Castaño Eloy, Lecru Line A, Pressanti Charline
1 UDEAR, Université de Toulouse, INSERM, ENVT, Toulouse, France.
2 Medical Department, Virbac SA, Carros, France.
J Feline Med Surg. 2018 Jun;20(6):587-590. doi: 10.1177/1098612X17715153. Epub 2017 Jun 19.
Objectives Few data are available concerning therapeutic aspects of feline trombiculiasis. This study evaluated the efficacy of a 10% w/v fipronil-based spot-on solution in 15 cats with natural Neotrombicula species infestation. Methods Ten cats received 1 drop per affected site on day (D)0 and D14, with the rest of the 0.5 ml pipette applied on the skin between the shoulders. Five cats served as non-treated controls. Parasite score (0 = absent; 3 = severe, >10 parasites/zone) was assessed on D0, D14 and D28 on all animals. Skin lesions (SCORing Feline Allergic Dermatitis lesion severity scale [SCORFAD]) and investigator pruritus scale (IPS; 0 = cat comfortable, grooming like any normal cat; 4 = cat uncomfortable, pruritic all the time) were assessed on treated cats on the same days. Global assessment of efficacy, tolerance and ease of use (GAS; 1 = very poor; 5 = excellent) was assessed on D28. Results All the cats completed the study. Parasite scores of the control cats were maintained throughout the trial (mean ± SD: D0 4 ± 0.7, D14 3.2 ± 1.1 and D28 3.2 ± 0.4). In treated cats, SCORFAD (D0 3.2 ± 5.4, D14 1.1 ± 2.1 [ P <0.002] and D28 0.5 ± 1.3 [ P <0.002]), parasite (D0 3.9 ± 1.3, D14 1.2 ± 0.8 [ P <0.005] and D28 0.4 ± 0.5 [ P <0.005]) and IPS (D0 1 ± 1.2, D14 0.5 ± 1.1 [ P <0.05] and D28 0.3 ± 0.7 [ P <0.05]) scores significantly decreased throughout the trial. On D28, the GAS was 4.2 ± 0.9. There were no adverse effects from treatment. Conclusions and relevance The 10% w/v fipronil preparation appeared to be effective, safe and practical in the treatment of localised Neotrombicula species infestation in these cats.
目的 关于猫恙螨病治疗方面的数据很少。本研究评估了一种10%（w/v）基于氟虫腈的滴剂溶液对15只自然感染新恙螨属物种的猫的疗效。方法 10只猫在第0天（D0）和第14天（D14），每个感染部位滴1滴，其余0.5毫升滴管溶液涂抹于两肩之间的皮肤上。5只猫作为未治疗的对照。在D0、D14和D28对所有动物评估寄生虫评分（0 = 无；3 = 严重，>10只寄生虫/区域）。在相同日期对治疗的猫评估皮肤病变（猫过敏性皮炎病变严重程度评分量表[SCORFAD]）和研究者瘙痒量表（IPS；0 = 猫舒适，像正常猫一样梳理毛发；4 = 猫不舒服，一直瘙痒）。在D28评估疗效、耐受性和易用性的总体评估（GAS；1 = 非常差；5 = 优秀）。结果 所有猫完成了研究。对照猫的寄生虫评分在整个试验中保持稳定（平均值±标准差：D0 4±0.7，D14 3.2±1.1，D28 3.2±0.4）。在治疗的猫中，SCORFAD（D0 3.2±5.4，D14 1.1±2.1 [P<0.002]，D28 0.5±1.3 [P<0.002]）、寄生虫（D0 3.9±1.3，D14 1.2±0.8 [P<0.005]，D28 0.4±0.5 [P<0.005]）和IPS（D0 1±1.2，D14 0.5±1.1 [P<0.05]，D28 0.3±0.7 [P<0.05]）评分在整个试验中显著降低。在D28，GAS为4.2±0.9。治疗没有不良反应。结论及相关性 10%（w/v）氟虫腈制剂在治疗这些猫的局部新恙螨属物种感染方面似乎有效、安全且实用。
